
|Videos|July 7, 2016
The Impact of PCSK9 Inhibitors on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Advertisement
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
2
Clots, Catheters, and Clinical Pearls: Pulmonary Embolism Updates for Practicing Pharmacists
3
Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma
4
Single-Shot Respiratory Vaccine Could Transform Pharmacist Counseling and Immunization Rates
5











































































































